EyeGene Inc Cash Flow Conversion Efficiency
EyeGene Inc cash flow conversion efficiency. Based on the latest financial reports, EyeGene Inc (185490) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.13 Billion ≈ $-2.12 Million USD) by net assets (₩50.92 Billion ≈ $34.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of EyeGene Inc (2014–2025)
Cash flow conversion efficiency of EyeGene Inc from 2014 to 2025. This chart illustrates how EyeGene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 185490 share price today for real-time trading data and today's change.
EyeGene Inc Cash Flow Conversion Ratio Explained
EyeGene Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
EyeGene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EyeGene Inc ranked by their cash flow conversion efficiency. Also see 185490 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
StoneBridge Ventures Inc.
KQ:330730
|
-0.023x |
|
GAMEVIL Inc
KQ:063080
|
-0.033x |
|
180 Degree Capital Corp
NASDAQ:TURN
|
-0.083x |
|
Diatreme Resources Ltd
AU:DRX
|
-0.020x |
|
Lowell Resources Fund
AU:LRT
|
0.028x |
|
PA Nova S.A.
WAR:NVA
|
-0.001x |
|
Lida Holdings Ltd
TW:4552
|
0.005x |
|
Linz Textil Holding AG
VI:LTH
|
0.058x |
Annual Cash Flow Conversion Efficiency for EyeGene Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of EyeGene Inc from 2014 to 2025. Review 185490 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩54.25 Billion ≈ $36.77 Million |
₩-5.98 Billion ≈ $-4.05 Million |
-0.110x | +54.42% |
| 2024-12-31 | ₩50.32 Billion ≈ $34.10 Million |
₩-12.17 Billion ≈ $-8.25 Million |
-0.242x | +22.45% |
| 2023-12-31 | ₩64.33 Billion ≈ $43.60 Million |
₩-20.07 Billion ≈ $-13.60 Million |
-0.312x | -12.09% |
| 2022-12-31 | ₩66.73 Billion ≈ $45.22 Million |
₩-18.57 Billion ≈ $-12.58 Million |
-0.278x | +17.49% |
| 2021-12-31 | ₩88.97 Billion ≈ $60.29 Million |
₩-30.00 Billion ≈ $-20.33 Million |
-0.337x | +55.40% |
| 2020-12-31 | ₩12.90 Billion ≈ $8.74 Million |
₩-9.75 Billion ≈ $-6.61 Million |
-0.756x | -72.94% |
| 2019-12-31 | ₩19.03 Billion ≈ $12.90 Million |
₩-8.32 Billion ≈ $-5.64 Million |
-0.437x | -36.42% |
| 2018-12-31 | ₩23.34 Billion ≈ $15.82 Million |
₩-7.48 Billion ≈ $-5.07 Million |
-0.321x | -12.64% |
| 2017-12-31 | ₩23.75 Billion ≈ $16.10 Million |
₩-6.76 Billion ≈ $-4.58 Million |
-0.285x | +23.06% |
| 2016-12-31 | ₩16.19 Billion ≈ $10.97 Million |
₩-5.99 Billion ≈ $-4.06 Million |
-0.370x | -87.96% |
| 2015-12-31 | ₩22.76 Billion ≈ $15.43 Million |
₩-4.48 Billion ≈ $-3.04 Million |
-0.197x | +68.29% |
| 2014-12-31 | ₩3.85 Billion ≈ $2.61 Million |
₩-2.39 Billion ≈ $-1.62 Million |
-0.621x | -- |
About EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more